Why the study?
Pulmonary hypertension is a debilitating disease with a poor overall prognosis, prompting review of pulmonary artery denervation as an emerging treatment.
Does pulmonary artery denervation improve hemodynamics, functionality, and REVEAL scores in patients with pulmonary hypertension?
Does pulmonary artery denervation improve hemodynamics, functionality, and REVEAL scores in patients with pulmonary hypertension?
Pulmonary artery denervation is a promising emerging interventional treatment that may improve hemodynamics and functional outcomes in patients with pulmonary hypertension.
PADN may benefit select PH patients; leaves open efficacy confirmation in randomized trials before practice change.
Pulmonary hypertension (PH) is a debilitating disease with a poor overall prognosis. Pulmonary artery denervation (PADN) has emerged as a promising new treatment which has been shown to improve hemodynamics, functionality, and REVEAL scores for patients with PH. This article reviews notable updates in the management of PH since the 6th World Symposium on PH, the pathophysiology of PH, how PADN may work given the pathophysiology of PH, and focuses on evidence from the eleven studies supporting the use of PADN from trials that include human participants.
No takes yet. Share an insight, caveat, or question.
McMaster et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: